Table 7.4Global assessment (early vs delayed treatment)

StudyOutcomesFollow-upResult – best treatment
One RCT226,227
Level 1++
Patient’s and physician’s global assessment of therapeutic benefit (MD 0.67 and 0.57)36 weeksEarly (p=0.01 and 0.032)
3-year follow-upNS
One cohort study236
Level 2+
Patient’s and physician’s global assessment (3 years: MD 29% and 32%)3 months and 3 yearsEarly (p <0.05)

From: 7, Pharmacological management

Cover of Rheumatoid Arthritis
Rheumatoid Arthritis: National Clinical Guideline for Management and Treatment in Adults.
NICE Clinical Guidelines, No. 79.
National Collaborating Centre for Chronic Conditions (UK).
Copyright © 2009, Royal College of Physicians of London.

All rights reserved. No part of this publication may be reproduced in any form (including photocopying or storing it in any medium by electronic means and whether or not transiently or incidentally to some other use of this publication) without the written permission of the copyright owner. Applications for the copyright owner’s written permission to reproduce any part of this publication should be addressed to the publisher.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.